Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization

American Journal of Health-System Pharmacy

Volumn 65, Issue 12, 2008, Pages 1148-1153

  Aramwit, Pornanong ^a   Pruksananonda, Kamthorn ^a   Kasettratat, Narat ^a   Jammeechai, Karnphat ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Somdej Prapinklao Hospital   (Thailand)

Author keywords

Buserelin acetate; Dosage schedules; Fertility agents; Fertilization in vitro; Gonadotropin chorionic; Ovarian hyperstimulation syndrome; Toxicity; Urofollitropin

Indexed keywords

ALBUMIN; BUSERELIN; BUSERELIN ACETATE; C REACTIVE PROTEIN; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PLASMA SUBSTITUTE; RECOMBINANT FOLLITROPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; ASIAN; BLOOD CELL COUNT; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED OVARIAN HYPERSTIMULATION; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LEUKOCYTE COUNT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OOCYTE RETRIEVAL; OUTPATIENT; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; THAILAND; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 45749095944     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070566     Document Type: Article

References (34)

1. Al-Ramahi M. Severe OHSS: decreasing the risk of severe ovarian hyperstimulation syndrome. Hum Reprod. 1999; 14:2421-2.
2. Delvinge A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8:559-77.
3. Delbaere A, Smits G, De Leener A et al. Understanding ovarian hyperstimulation syndrome. Endocrine. 2005; 26:285-90.
4. Budev M, Arroliga A, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005; 33:S301-6.
5. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003; 9:77-96.
6. Ragni G, Vegetti W, Riccaboni A et al. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod. 2005; 20:2421-5.
7. Konig E, Bussen S, Sutterlin M et al. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod. 1998; 13:2421-4.
8. Nargund G, Hutchison L, Scaramuzzi R et al. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online. 2007; 14:682-5.
9. Papanikolaou E, Pozzobon C, Kolibianakis E et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006; 85:112-20.
10. Golan A, Ron-El R, Herman A et al. Ovarian hyperstimulation syndrome, D-Trp-6 luteinizing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril. 1988; 50:912-6.
11. Navot D, Relou A, Birkenfeld A et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1988; 159:210-5.
12. Enskog A, Henriksson M, Unander M et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999; 71:808-14.
13. Rush E, Goedecke J, Jennings C et al. BMI, fat and muscle differences in urban women of five ethnicities from two countries. Int J Obes (Lond). 2007; 31:1232-9.
14. Palep-Singh M, Picton H, Vrotsou K et al. South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. Eur J Obstet Gynecol Reprod Biol. 2007; 134:202-7.
15. Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004; 3:161-71.
16. Golan A, Ron-El R, Herman A et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; 44:430-40.
17. Delvigne A, Dubois M, Battheu B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod. 1993; 8:1361-6.
18. Lyons C, Wheeler C, Frishman G et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. 1994; 9:792-9.
19. Montanelli L, Delbaere A, Di Carlo C et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2004; 89:1255-8.
20. Blankstein J, Shalev J, Saadon T et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril. 1987; 47:597-602.
21. Reljic M, Vlaisavljevic V, Gavric V et al. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome. J Reprod Med. 1999; 44:713-8.
22. Schenker J. Clinical aspects of ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 1999; 85:13-20.
23. Abramov Y, Schenker J, Lewin A et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod. 1996; 11:1381-6.
24. Revel A, Barak V, Lavy Y et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril. 1996; 66:66-71.
25. Artini P, Monti M, Fasciani A et al. Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 2002; 101:169-74.
26. Asch R, Li H, Balmaceda J et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991; 6:1395-9.
27. Haning RJ, Austin C, Carlson I et al. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril. 1983; 40:31-6.
28. MacDougall M, Tan S, Balen A et al. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod. 1993; 8:233-7.
29. Danninger B, Brunner M, Obruca A et al. Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation. Hum Reprod. 1996; 11:1597-9.
30. Buyalos R, Lee C. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Fertil Steril. 1996; 65:1-10.
31. Dor J, Shulman A, Levran D et al. The treatment of patients with polycystic ovarian syndrome by in vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. Hum Reprod. 1990; 5:816-8.
32. Shulman A, Dor J. In vitro fertilization treatment in patients with polycystic ovaries. J Assist Reprod Genet. 1997; 14:7-10.
33. Ito M, Harada T, Iwabe T et al. Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid. J Assist Reprod Genet. 2000; 17:118-20.
34. Chen C, Chen H, Lu H et al. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod. 2000; 15:1037-42.